• Sellas lost a binding arbitration against 3D Medicines at the HKIAC, with the arbitrator dismissing its claims on July 24, 2026.
• The arbitrator allocated about $1 million of 3D Medicines’ legal fees and costs to be paid by Sellas.
• 3D Medicines plans to keep developing and commercializing galinpepimut-S in Greater China under the exclusive license agreement.
• Potential future milestone payments under the license totaled $191.5 million as of March 31, 2026, including a disputed $13 million milestone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-087110), on July 27, 2026, and is solely responsible for the information contained therein.